The unique property of GRK5 of simultaneously being an ENaC inhibitor33 is desirable for reversing CF symptoms in the clinic because the loss of Cl− secretion via CFTR due to CF-causing variants is accompanied by Na+ hyperabsorption via ENaC, which exacerbates airway dehydration.51 This evidence concerns the gene CFTR and cystic fibrosis.